Thalidomide inhibits early atherogenesis in apoE-deficient mice

APMIS, Supplement

Volumn 111, Issue 109, 2003, Pages 113-116

  Chew, Michelle ^a   Zhou, Ji ^a,b   Daugherty, Alan ^c   Eriksson, Tommy ^d   Ellermann Eriksen, Svend ^a   Hansen, Peter Riis ^e   Falk, Erling ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF KENTUCKY   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Cytokines; Inflammation; Pathology; Thalidomide; TNF

Indexed keywords

APOLIPOPROTEIN E; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; DRUG IMPLANT; DRUG PELLET; DRUG SCREENING; DRUG TOLERANCE; FEMALE; HOMOZYGOSITY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RANDOMIZATION; SUSTAINED DRUG RELEASE; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODEL; DRUG ANTAGONISM; GENETICS;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; MICE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037663818     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74
2. Libby P, Ridker PM, Maseri A. Inflammation and athe rosclerosis.Circulation 2002;105:1135-43
3. Hansson GK and Libby P. Immune functions of the vessel wall. Harwood Academic Publishers, 1996:143-58
4. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumour necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302
5. Le Boeuf RC, Schreyer SA. The role of tumour necrosis factor-α receptors in atherosclerosis. Trends Cardiovasc Med 1998;8:131-8
6. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type I matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999;99:3103-9
7. Libby P, Galis ZS. Cytokines regulate genes involved in atherogenesis. Annals NY Acad Sci 1995;748:158-68
8. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumour necrosis factor receptor p55. J Biol Chem 1996; 271:26174-8
9. Eriksson T, Björkman S, Roth B, Fyge Å, Höglund P. Stereospecific determination, chiral inversion in-vitro and pharmacokinetics in humans of the enatiomers of thalidomide. Chirality 1995:7:44-52
10. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumour necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675-80
11. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflammation 1996;46:177-211
12. Corral LG, Muller GW, Moreira AL, Chen Y, Stirling D, Kaplan G. Selection of novel analogues of thalidomide with enhanced tumour necrosis α activity. Molecular Medicine 1996;2:506-15
13. Moreira AL, Tsenova-Berkova L, Wang J, Laochumroonvorapong P, Freeman S, Freedman VH, et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle and Lung Disease 1997:78:47-55
14. Eriksson T, Björkman S, Fyge Å. Determination of thalidomide in plasma and blood by high performance liquid chromatography: avoiding hydrolytic degradation. J Chromatography 1992;582:211-6
15. Hansen PR, Chew M, Zhou J, Daugherty A, Heegaard N, Jensen P, Mouritsen S, Falk E. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. Atherosclerosis 2001;158:87-94.
16. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. 1. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993;67:1-17
17. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantoy R, Levin LF, et al. Genetic background determines the extent of atherosclerosis in apoE deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1960-8